ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2673

Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis

Diane Lacaille1, Coraline Danieli2, Kasra Moolooghy1 and Michal Abrahamowicz3, 1Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 2Research Institute of McGill University Health Center (RI-MUHC), Montreal, QC, Canada, 3McGill University, Verdun, Canada

Meeting: ACR Convergence 2024

Keywords: Administrative Data, glucocorticoids, Mortality, population studies, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 19, 2024

Title: Abstracts: RA – Treatment II: Refining Use of Established Therapies

Session Type: Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Glucocorticosteroid (GC) use is associated with increased mortality risk, especially from cardiovascular diseases (CVD) and infections, with dose and duration of use influencing risk. How long the impact lasts after stopping GC, and how this is influenced by duration of previous use, are not known.  This study aims to estimate how the risk of mortality from CVD and infections is associated with i) cumulative duration of past GC use and ii) time since cessation of GC.

Methods: We conducted a longitudinal study of a population-based incident RA cohort, using administrative health data in a universal health care system. All incident RA cases in British Columbia, Canada, who met RA definition between 01/01/1996 and 12/31/2013, using a 5 yr look back period, were identified using physician billing data and followed until 12/31/2018. Oral GC exposure was measured as time-varying variables representing: current use, total cumulative duration of use, and time since discontinuation. Deaths with CVD or infections as the primary cause were identified from death certificates. Each incident user of GC was followed from time of starting GC (if started after RA index date) or of meeting RA criteria (if GC started before RA index date), using delayed entry to avoid immortal time bias, until death or censoring due to moving out of province or end of F/U. Multivariable conventional Cox PH model  and its flexible extensions with  non-linear effects were used to estimate the risk of death associated with cumulative duration of GC use, time since GC cessation and time varying interactions between the 2, adjusting for potential confounders (sociodemographic and comorbidities measured at index date and other RA meds as time-varying covariates). 

Results: We identified 28,078 incident GC users (55.9% of cohort), with mean (SD) and median (25;75Q) GC use duration of 603 (1116) and 131(18;598) days. See Table 1 for sample characteristics. We observed 2,489 CVD deaths and 387 from infections. In conventional Cox PHM risk of CVD / infection mortality increased by 7.5% / 6.8% for every year of GC use; and decreased by 1.3% / 4.9% for every year after stopping GC. Flexible extensions revealed non-linear relationships for both variables (Figure 1).  Duration of previous use influenced risk after cessation (Figure 2). Risk decreased to that of someone prior to starting GC at 1.5, 3.5 and 10 years after cessation if GC had been used for 6,12, and 24 months for CVD deaths and at 2.5, 3.5, and 5.5 years, resp. for deaths from infections. Risk of death from CVD and infections never returned to pre-GC use risk in patients who used GC for  > 2 years and  > 3 years, respectively.  

Conclusion: Despite advances in RA therapy GC are still commonly used and for long periods in some. The increased mortality risk from CVD and infections lasts for a substantial time after cessation, and never returns to that pre-GC with prolonged use. These findings are of high clinical relevance to people with rheumatoid arthritis and physicians, inform shared decision-making for starting and stopping GC, and provide evidence in support of RA guidelines recommending use of GC at lowest dose for shortest periods possible. 

Supporting image 1

Table 1. Baseline characteristics of study sample (GC users) and entire incident RA cohort

Supporting image 2

Figure 1. Estimates from flexible extension of multivariable Cox models (spline-based) estimating the non-linear (NL) effect of cumulative duration of past GC use (panels on left) and time since cessation of GC (panels on right) on the hazard of mortality due to CVD (top panels) and mortality due to infections (bottom panels).

Supporting image 3

Figure 2. Joint effect of Time since cessation of GC treatment and Cumulative duration of past GC use on the hazard of mortality due to CVD (left panel) and mortality due to infections (right panel)


Disclosures: D. Lacaille: None; C. Danieli: None; K. Moolooghy: None; M. Abrahamowicz: None.

To cite this abstract in AMA style:

Lacaille D, Danieli C, Moolooghy K, Abrahamowicz M. Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/changes-in-mortality-risk-after-stopping-glucocorticosteroids-a-population-based-study-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-mortality-risk-after-stopping-glucocorticosteroids-a-population-based-study-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology